ACLA Elects Officers for 2025-2027 Board of Directors
Washington, D.C.— The American Clinical Laboratory Association (ACLA) elected its Board of Directors for the 2025-2027 term, reaffirming its commitment to advancing diagnostic innovation and patient care. The election took place today at the 2025 ACLA Annual Meeting.
William G. Morice II, M.D., Ph.D., president and CEO of Mayo Collaborative Services/Mayo Clinic Laboratories, has been elected as ACLA Board Chair. Adam H. Schechter, chairman, CEO, and president of Laboratory Corporation of America, has been elected as Vice Chair, and Kevin T. Conroy, chairman and CEO of Exact Sciences Corporation, has been elected as Treasurer.
ACLA also welcomes its full 2025-2027 Board of Directors, which includes returning and newly elected members:
- Steve Chapman, CEO of Natera (first-time member)
- Jim Davis, chairman, CEO, and president of Quest Diagnostics
- Paul J. Diaz, president and CEO of Myriad Genetics, Inc.
- Martin Price, executive chairman and CEO of HealthTrackRx (first-time member)
- Cory A. Roberts, M.D., M.B.A., CEO of Sonic Healthcare USA
- Chris Smith, CEO of NeoGenomics Laboratories
- Katherine Stueland, president and CEO of GeneDx (first-time member)
- Andy Theurer, CEO of ARUP Laboratories
- Susan Van Meter, president of ACLA
- Elias Zerhouni, M.D., president of OPKO Health/BioReference Health
“These esteemed industry leaders bring unparalleled expertise and a steadfast commitment to ensuring patients and providers have access to high-quality, innovative diagnostic services,” said ACLA President Susan Van Meter. “Their leadership will be instrumental in advancing policies that strengthen clinical laboratories’ ability to deliver timely, reliable testing — helping to prevent disease, improve health outcomes, and reduce health care costs.”
Learn more about ACLA here.
###
The American Clinical Laboratory Association (ACLA) is the national trade association representing leading laboratories that deliver essential diagnostic health information to patients and providers by advocating for policies that expand access to the highest quality clinical laboratory services, improve patient outcomes, and advance the next generation of personalized care.
